Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to compare the outcomes of first-line systemic targeted therapy (TT) and immunotherapy (IT) in patients with metastatic renal cell carcinoma (mRCC). Materials and Methods This study was a retrospective review of the data of 262 patients treated with systemic IT or TT with tyrosine kinase inhibitors between 2003 and 2013. The objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were assessed using Response Evaluation Criteria in Solid Tumor ver. 1.0 criteria and the Kaplan-Meier method with log-rank test. Results During the median 4.3-month treatment and the 24-month follow-up period, the ORR/PFS/OS of the overall first-line and second-line therapy were 41.9%/8.1 months/16.8 months and 27.5%/6.5 months/15.3 months, respectively. The first-line TT/IT/sequential IT had a PFS of 9.3/6.4/5.7 months and an OS of 15.8/16.5/40.6 months (all p < 0.05). The second-line of TT/IT had a PFS of 7.1/2.1 months (both p < 0.05) and an OS of 16.6/8.6 months (p=0.636), respectively. Pazopanib provided the best median PFS of 11.0 months (p < 0.001) and a quadruple IT regimen had a superior PFS (p=0.522). For OS, sequential treatment with IT and TT was superior compared to treatment with either IT or TT alone (40.6/16.5/15.8 months, p=0.014). The prognosis according to the Memorial Sloan Kettering Cancer Center model showed that favorable/intermediate/poor risk groups had a PFS of 8.5/10.4/2.3 months, and an OS of 43.1/20.4/5.6 months, respectively. The prognosis calculated using the Heng model showed that the favorable/intermediate/poor risk groups had a PFS of 9.2/3.9/2.7 months, and an OS of 32.4/16.5/6.1months, respectively (all p < 0.001). Conclusion In patients with mRCC, TT provided a better PFS and OS compared with IT.
Abstract
Purpose The purpose of this study is to compare the outcomes of first-line systemic targeted therapy (TT) and immunotherapy (IT) in patients with metastatic renal cell carcinoma (mRCC). Materials and Methods This study was a retrospective review of the data of 262 patients treated with systemic IT or TT with tyrosine kinase inhibitors between 2003 and 2013. The objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were assessed using Response Evaluation Criteria in Solid Tumor ver. 1.0 criteria and the Kaplan-Meier method with log-rank test. Results During the median 4.3-month treatment and the 24-month follow-up period, the ORR/PFS/OS of the overall first-line and second-line therapy were 41.9%/8.1 months/16.8 months and 27.5%/6.5 months/15.3 months, respectively. The first-line TT/IT/sequential IT had a PFS of 9.3/6.4/5.7 months and an OS of 15.8/16.5/40.6 months (all p < 0.05). The second-line of TT/IT had a PFS of 7.1/2.1 months (both p < 0.05) and an OS of 16.6/8.6 months (p=0.636), respectively. Pazopanib provided the best median PFS of 11.0 months (p < 0.001) and a quadruple IT regimen had a superior PFS (p=0.522). For OS, sequential treatment with IT and TT was superior compared to treatment with either IT or TT alone (40.6/16.5/15.8 months, p=0.014). The prognosis according to the Memorial Sloan Kettering Cancer Center model showed that favorable/intermediate/poor risk groups had a PFS of 8.5/10.4/2.3 months, and an OS of 43.1/20.4/5.6 months, respectively. The prognosis calculated using the Heng model showed that the favorable/intermediate/poor risk groups had a PFS of 9.2/3.9/2.7 months, and an OS of 32.4/16.5/6.1months, respectively (all p < 0.001). Conclusion In patients with mRCC, TT provided a better PFS and OS compared with IT.
참고문헌 (24)
- Motzer RJ, "NCCN clinical practice guidelines in oncology : kidney cancer", J Natl Compr Canc Netw, 7, pp.618~630 (2009)
- Oudard S, "Treatment options in renal cell carcinoma: past, present and future", Ann Oncol, 18(Suppl 10), pp.25~31 (2007)
- Fossa SD, "Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma : results of a randomised phase II study", Br J Urol, 64, pp.468~471 (1989)
- Pyrhonen S, "Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer", J Clin Oncol, 17, pp.2859~2867 (1999)
- Fisher RI, "Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma", Cancer J Sci Am, 6(Suppl 1), pp.55~57 (2000)
- Fyfe G, "Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy", J Clin Oncol, 13, pp.688~696 (1995)
- 조인창, "Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma", Investigative and Clinical Urology, 53(4), pp.217~228 (2012), 대한비뇨기과학회[DOI]
- 이지한, "Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea", Investigative and Clinical Urology, 51(6), pp.379~385 (2010), 대한비뇨기과학회
- Heng DY, "Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study", J Clin Oncol, 27, pp.5794~5799 (2009)
- Motzer RJ, "Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma", J Clin Oncol, 20, pp.289~296 (2002)
- Motzer RJ, "Systemic therapy for renal cell carcinoma", J Urol, 163, pp.408~417 (2000)
- McDermott DF, "Update on the application of interleukin-2 in the treatment of renal cell carcinoma", Clin Cancer Res, 13(2 Pt 2), pp.716~720 (2007)
- Escudier B, "Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma", J Clin Oncol, 27, pp.1280~1289 (2009)
- Hutson TE, "Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma", J Clin Oncol, 28, pp.475~480 (2010)
- Desai AA, "Novel kinase inhibitors in renal cell carcinoma : progressive development of static agents", Curr Urol Rep, 7, pp.16~22 (2006)
- Akaza H, "Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma : efficacy, safety and biomarker analyses in 1689 consecutive patients", Jpn J Clin Oncol, 45, pp.576~583 (2015)
- Akaza H, "A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan : results of over 3200 consecutive cases in post-marketing all-patient surveillance", Jpn J Clin Oncol, 45, pp.953~962 (2015)
- Gore ME, "Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma", Br J Cancer, 113, pp.12~19 (2015)
- Albiges L, "Complete remission with tyrosine kinase inhibitors in renal cell carcinoma", J Clin Oncol, 30, pp.482~487 (2012)
- Johannsen M, "Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy", Ann Oncol, 22, pp.657~663 (2011)
- Matrana MR, "Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with frontline pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI)or mammalian target of rapamycin inhibitors (mTORi): a single institution experience", BJU Int (2015)[DOI]
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Ward E, "Cancer disparities by race", ethnicity and socioeconomic status, 2004, pp.54, 78~93
- Sadeghi S, "Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma : feasibility and clinical outcome", Cancer, 118, pp.3277~3282 (2012)